JOHNSON & JOHNSON is 456.8x more valuable than MapLight Therapeutics, Inc. by market capitalization ($574.10 B vs $1.26 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MPLT | JNJ |
|---|---|---|
| Market cap | $1.26 B | $574.10 B |
| US-listed rank | #2467 | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | -$161.15M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 144 | 984 |
JOHNSON & JOHNSON is 456.8x more valuable than MapLight Therapeutics, Inc. by market capitalization ($574.10 B vs $1.26 B).
Full pages: MapLight Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.